Jump to main content
Topic: Specialty Drugs
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
Read More
-
Production Plus Profit Pricing (P-quad) FAQ
Read More
-
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Read More
-
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
Read More
-
The Drugs at the Heart of Our Pricing Crisis
Read More
-
Biosimilars: Market Changes do not equal policy success
Read More
-
Ethics of Clinical Trials to Evaluate Biosimilars
Read More
-
Bottom-Up Pricing Estimate for P-quad
Read More
-
Modeling P-quad
Read More
-
Time to Throw in the Towel on Biosimilars
Read More